With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

Recent market research reveals that glucagon-like peptide-1 (GLP-1) injections are set to dominate the obesity treatment ...

The study showed diabetic patients taking GLP-1 drugs, such as semaglutide and tirzepatide, faced significantly lower risks of 30-day readmission, wound re-opening and hematoma after surgery, compared ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...

MBX Biosciences reports Phase 1 trial results for MBX 1416, a GLP-1 receptor antagonist for post-bariatric hypoglycemia. Phase 2 starts in 2025.

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...